Multiple Myeloma
Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma; Status: Recruiting; Study ID: NCT01503242
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01208662
A Single-Arm, Open-Label, Phase II Clinical Trial Evaluating Disease Response following Treatment with Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients with High-risk, Smoldering Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma (MM); Status: Recruiting; Study ID: NCT01302886
An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma (MM); Status: Recruiting; Study ID: NCT00963820
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Hematologic Malignancies; Multiple Myeloma (MM); Status: Recruiting; Study ID: NCT01122875
An Open-Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Closed; Study ID: NCT01063907
A Phase 1/2 Study Of Arry-520 In Patients With Relapsed Or Refractory Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT00821249
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Relapsed Multiple Myeloma; Status: Recruiting; Study ID: NCT01080391
Join Us On